Phosphatidylserine Proposition 65 Statement Review for US Supplement Brands

North American phosphatidylserine buyers often clear the early sourcing questions quickly: source route, target assay, MOQ, packing size, batch COA availability, supplier qualification, and U.S. import document flow. Then a downstream brand, contract manufacturer, distributor, or California retailer raises a narrower question that can stall the whole file: do we have enough supplier support to answer a Proposition 65 request for this exact phosphatidylserine route?

The short answer is that a phosphatidylserine Proposition 65 review should be handled as a California exposure and document-control workflow, not as a casual request for a one-line declaration. California's Office of Environmental Health Hazard Assessment explains that Proposition 65 requires warnings about significant exposures to chemicals known to cause cancer or reproductive toxicity, while exposures below applicable safe-harbor levels are exempt. The California legislative text in Health and Safety Code section 25249.6 frames the duty as providing a clear and reasonable warning before knowingly and intentionally exposing an individual to a listed chemical. The practical implication is an inference from those official sources: a buyer should not treat a raw-material pass/fail note, or a generic heavy-metals email, as if it automatically resolves the California warning question for the finished commercial route.

Proposition 65 questions also tend to arrive late, when the formula, artwork, or customer file is already moving. At that stage, teams need a controlled process that separates ingredient-level supplier evidence from the final exposure and warning decision.

This article is written for U.S. ingredient importers, supplement manufacturers, private-label brands, distributors, procurement managers, quality teams, and regulatory reviewers handling California-facing supplement projects. It focuses on supplier qualification, data routing, and approval workflow. It does not provide legal advice and it does not make medical treatment claims.

Where Nutranexa is mentioned, only verified site facts are used. The current site identifies the operating company as Shandong Baianrui Biopharmaceutical Co., Ltd., founded in 2013, operating a 110,000+ m2 campus, and primarily serving Europe and North America. It provides separate buyer paths for Phosphatidylserine, Soja Phosphatidylserine, and Girasol Phosphatidylserine, along with Calidad e I+D, Fabricación, and Contactar con Ventas pages for current document requests. Final California decisions should still depend on the exact route, the brand's intended daily serving, and the buyer's own legal and quality review path.

The Short Answer Buyers Need First

If your team is reviewing phosphatidylserine for a California-facing supplement or nutrition project, the simplest workable Proposition 65 process is:

1. Lock the exact route first: general PS, soy PS, or sunflower PS.
2. Confirm whether the question is about supplier heavy-metals support, a customer questionnaire, or a finished-product California warning decision.
3. Review the current COA path, specification, and any available contaminant-support file together with the intended daily serving.
4. Keep the supplier file separate from the final Proposition 65 warning determination.
5. Record who owns the next answer: importer, contract manufacturer, brand, or legal/regulatory lead.

That is the practical distinction buyers often miss. Proposition 65 is not answered by the product name alone, and it is not answered by a generic statement that ignores exposure assumptions. OEHHA's lead page, for example, lists oral safe-harbor levels of 15 micrograms per day for cancer and 0.5 micrograms per day for reproductive toxicity. That does not make every PS project a lead-warning project. It shows why the California review depends on the listed chemical and the actual intake scenario being evaluated.

Why Proposition 65 Review Is Its Own Buyer Task

Proposition 65 is exposure-based, not ingredient-name-based

One reason teams mishandle Proposition 65 is that they treat it like a naming problem. They ask whether phosphatidylserine is "Prop 65 compliant" as if the answer sits inside the ingredient name or a generic supplier claim.

That is not how the official California framework works. OEHHA explains that a product does not require a warning simply because it contains a listed chemical; the question is whether the exposure triggers the law. The Proposition 65 list covers a wide range of chemicals, and some chemicals have established NSRLs or MADLs while others do not.

For phosphatidylserine buyers, the business lesson is straightforward:

That is why Proposition 65 review belongs beside, not inside, general specification review. Phosphatidylserine COA, Specification, and Certificate Review helps buyers compare document types. Can US Manufacturers Rely on a PS Supplier COA? explains why a contract manufacturer may need more than a supplier batch report. Proposition 65 review answers a narrower question: what supplier evidence exists, what exposure assumptions are being used, and who owns the California warning decision?

FDA supplement quality controls still do not answer the California warning question by themselves

Some buyers assume the California issue disappears if the ingredient already fits ordinary U.S. supplement quality controls. That is too broad.

FDA's dietary supplement CGMP framework in 21 CFR Part 111 requires quality control operations to ensure supplement quality, while FDA separately notes that toxic elements such as arsenic, lead, cadmium, and mercury matter in foods and dietary supplements. Those are important controls, but they do not automatically answer the Proposition 65 question, because California warning analysis is not identical to federal CGMP compliance.

The Six-Part Workflow for Reviewing a PS Proposition 65 Request

Lock the exact phosphatidylserine route and California sales path first

Before requesting any Proposition 65 support file, fix the commercial route in writing. Is the team comparing a general PS route for sourcing, or is it already quoting soy PS or sunflower PS? Will the finished product actually be sold in California, or is the question only being raised by a national distributor that wants one technical answer?

This matters because the California review becomes sloppy when the route and sales path are both moving. Without a stable route and market path, the review becomes a chain of email opinions instead of a controlled decision.

The opening note should usually record:

• exact product route
• intended finished daily serving or use assumption
• California sales expectation
• documents already in hand
• open Proposition 65 question still unresolved

Separate supplier support files from the finished-product warning decision

The second step is to separate what the supplier can support from what the finished-product owner must decide.

A phosphatidylserine supplier may be able to provide:

• current specification
• current batch COA or representative COA style
• route identity and source information
• contaminant-support data or statement path, if available
• general commercial clarification on MOQ, packing, and product route

The supplier usually does not own every downstream California decision. The brand, contract manufacturer, or other responsible business still has to decide whether the finished intake scenario leads to a warning and whether additional testing or calculations are required.

That distinction also lines up with California's legal structure. In practical B2B terms, a raw-material supplier can be an important evidence source without becoming the only owner of the downstream California answer.

Review COA data, specification language, and intended daily intake together

Once the file is assembled, buyers should review three things at the same time:

1. the exact phosphatidylserine route being quoted
2. the available ingredient-level contaminant or statement support
3. the finished-product intake assumption that will matter in California

That table is why a simple "passes heavy metals" note is rarely enough. It may help supplier qualification, but the California review still needs a defined exposure basis.

Map ownership across importer, contract manufacturer, and brand

The fourth step is to write down who owns which part of the answer. If nobody owns the California decision, sales will end up improvising it.

In a typical U.S. supplement project:

• the importer or procurement lead owns supplier collection
• QA reviews document completeness and consistency
• the contract manufacturer or brand owns formula-specific intake assumptions
• regulatory or legal review owns the final California warning position

That ownership split matters because Proposition 65 questions often appear at the moment a customer wants a yes-or-no answer.

Escalate immediately when the listed-chemical or exposure basis is unclear

Escalation is appropriate when:

• the file does not identify which listed chemical is driving the California question
• the project has no stable daily serving assumption yet
• the only evidence in hand is a generic COA with no route-specific interpretation
• the customer wants a "no warning" promise before the brand or contract manufacturer has completed its own review
• the route changed after the original support files were collected

The escalation note does not need to be complicated. It should say which route is under review, what California question remains open, what intake assumption is being used or is still missing, and who owns the next decision.

Close with a go, hold, or escalation decision

The final step is to record an outcome another team can use:

• Go: the route, supplier support, and California review ownership are aligned well enough for the current stage.
• Hold: the project may still be attractive, but the California question is not controlled enough yet.
• Escalate: the route needs additional testing, exposure review, or legal/regulatory sign-off before anyone makes a warning claim.

This closeout matters because Proposition 65 questions often resurface after sourcing is approved but before California sales or customer handoff.

Need a Current Support File for a California-Facing Project?

If your team is still relying on a generic heavy-metals email while comparing soy and sunflower phosphatidylserine routes for a California-facing supplement project, stop before the answer becomes a customer promise. Use Nutranexa's contact page to request the current specification path, COA path, and available contaminant-support file for the exact phosphatidylserine route under review.

The fastest inquiries usually include the route, intended daily serving, target market, commercial stage, and whether the request is coming from procurement, QA, a contract manufacturer, or a downstream brand team.

Common Mistakes in Phosphatidylserine Proposition 65 Review

Most failures here are workflow failures, not chemistry failures.

1. Asking whether phosphatidylserine is "Prop 65 compliant" before locking the exact route and finished-use assumption.
2. Treating a raw-material COA as if it automatically settles the California warning question.
3. Confusing federal supplement CGMP expectations with California warning analysis.
4. Letting sales promise "no warning required" before the responsible business has finished its exposure review.
5. Forgetting to identify which listed chemical, if any, is driving the request.
6. Reusing an old support file after the route, serving, or finished formula changed.

The practical fix is simple: keep one question at the center of the review. What supplier evidence exists for this exact phosphatidylserine route, what intake assumption is being used, and who owns the California warning decision?

How Verified Nutranexa Facts Fit This Workflow

For buyers evaluating Nutranexa, several verified site facts support a cleaner California-facing review process.

First, the site already separates Phosphatidylserine, Soja Phosphatidylserine, and Girasol Phosphatidylserine into distinct buyer paths. That helps teams keep the Proposition 65 review attached to one stable commercial route instead of one vague PS category.

Second, the site confirms useful supplier baseline facts for qualification: the company was founded in 2013, operates a 110,000+ m2 campus, and primarily serves Europe and North America.

Third, Nutranexa's public site provides request paths through Calidad e I+D, Fabricación, and Contactar con Ventas, which fits the workflow described here: request the current route-specific support file, then combine it with your own California serving and warning analysis.

Fourth, the site provides verified baseline handling facts for phosphatidylserine, including 25 kg MOQ y 25 kg netos por bidón packaging, together with public COA/specification evidence and factory, packaging, dispatch, and R&D context. Those facts help qualification, but they do not replace the California review described in this article.

Fuentes

• OEHHA: Proposition 65 Overview
• OEHHA: About Proposition 65
• OEHHA: Businesses and Proposition 65
• OEHHA: Proposition 65 in Plain Language
• OEHHA: Proposition 65 List
• OEHHA: Lead
• OEHHA: No Significant Risk Levels and Maximum Allowable Dose Levels
• California Legislative Information: Health and Safety Code Section 25249.6
• eCFR: 21 CFR Part 111
• FDA: Environmental Contaminants in Food

Preguntas frecuentes

Does phosphatidylserine need a Proposition 65 statement?

Often buyers ask for one when a product may be sold in California, but the useful question is narrower: what supplier support exists for the exact route, and who owns the final warning decision for the finished product?

Can a phosphatidylserine COA replace a Proposition 65 review?

No. A COA can be part of the evidence set, but Proposition 65 questions are usually about listed-chemical exposure under a defined intake scenario, not only about whether a raw material passed a general specification.

Is Proposition 65 review the same as a heavy-metals specification review?

No. Heavy-metals review checks analytical data and specification limits. Proposition 65 review asks how those data relate to listed chemicals, intake assumptions, and warning responsibility in California.

Who usually owns the final California warning decision?

Usually the finished-product owner, contract manufacturer, or brand regulatory/legal lead, not the raw-material supplier alone. The supplier supports the file, but the downstream business still owns its own exposure and warning analysis.

What should buyers request from Nutranexa for a California-facing PS project?

Request the exact route-specific specification path, COA path, and any available contaminant-support files for the quoted phosphatidylserine route, then align those files with the intended daily serving and the responsible business's California review.

Conclusion

Phosphatidylserine Proposition 65 review becomes manageable when buyers stop treating it as a generic declaration request and start treating it as a route-specific exposure and document-control task.

The strongest North American workflow is practical: lock the route first, separate supplier support from the finished-product warning decision, review the data together with the intake assumption, map ownership across importer, manufacturer, and brand, and close with one clear decision. That process helps buyers avoid a common qualification failure: the sourcing file looks complete, but nobody can show how the California answer was actually reached.

Próximos pasos recomendados

• Revisa el Phosphatidylserine página del producto.
• Comparar Soy PS y Sunflower PS.
• Verificar prueba de fabricación y Calidad e I+D.